title: [Hepatic recurrence after prophylactic hepatic arterial infusion of 5-fluorouracil for Dukes' C colorectal cancer--correlation with the expression of dihydropyrimidine dehydrogenase in the primary tumor].
abstract: OBJECTIVE
  The purpose of this study was twofold: (1) to disclose the intermediate outcome of a non-randomized trial of prophylactic hepatic arterial infusion chemotherapy (PHAI) for curatively resected Dukes' C colorectal cancer performed between November 1996 and April 2000, and (2) to examine the relationship between the expression of dihydropyrimidine dehydrogenase (DPD) in tumor tissue and the efficacy of this chemotherapy.
  
  
  METHODS
  The oncological outcomes were compared between patients (n = 28) receiving PHAI (5-FU: 500 mg/body/w x 50 cycles) plus oral administration of UFT-E (400 mg/body/day, for 24 months) and those (n = 21) receiving UFT-E alone. The levels of tumoral DPD were determined in a total of 43 patients (n = 25, PHAI group; n = 18, control group) by an enzyme-linked immunosorbent assay.
  
  
  RESULTS
  Seven (25%) in the PHAI group and four (19%) in the control group developed liver metastasis postoperatively. The liver metastasis-free survival was not different between the groups (p = 0.94). When the analysis was restricted to patients who developed liver metastasis, the duration from surgery to detecting liver metastasis tended to be longer in the PHAI group (p = 0.09). In addition, the overall survival tended to be better in the PHAI group (p = 0.12). In the control group, the level of DPD was higher in patients who developed liver metastases (n = 4) than in those who did not (n = 14, p = 0.04). However, in the PHAI group, the level of DPD was not different regardless of the occurrence of liver metastases (p = 0.30).
  
  
  CONCLUSIONS
  These results suggest that (1) PHAI is unlikely to improve the prognosis of Dukes' C patients remarkably, and (2) the efficacy of this regimen cannot be predicted by determining the levels of tumoral DPD.
authors.affiliation: Dept. of Surgery, Saitama Medical Center, Saitama Medical School.
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishida
authors.forename: Ikuya
authors.initials: I
authors.lastname: Takeuchi
authors.forename: Tomonori
authors.initials: T
authors.lastname: Ohsawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nakada
authors.forename: Naoki
authors.initials: N
authors.lastname: Ishizuka
authors.forename: Masaru
authors.initials: M
authors.lastname: Yokoyama
authors.forename: Shigehisa
authors.initials: S
authors.lastname: Inokuma
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Suzuki
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Yamada
authors.forename: Akio
authors.initials: A
authors.lastname: Odaka
authors.forename: Takanobu
authors.initials: T
authors.lastname: Hoshino
authors.forename: Nobuo
authors.initials: N
authors.lastname: Murata
authors.forename: Daijo
authors.initials: D
authors.lastname: Hashimoto
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: Takeshi
authors.initials: T
authors.lastname: Miura
mesh_terms: D000284:Administration, Oral; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D003110:Colonic Neoplasms / Q000473:pathology* / Q000601:surgery; D042943:Dihydrouracil Dehydrogenase (NADP); D004797:Enzyme-Linked Immunosorbent Assay; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D009364:Neoplasm Recurrence, Local; D010088:Oxidoreductases / Q000032:analysis*; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D000964:Antimetabolites, Antineoplastic; D005641:Tegafur; D014498:Uracil; D010088:Oxidoreductases; D042943:Dihydrouracil Dehydrogenase (NADP); D005472:Fluorouracil